CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 62 enrolled
Drug / intervention
Eribulin-LFdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01945710
NCT01945710Phase 1Completed
CompareCT.gov

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Eisai Limited·interventional·Posted Sep 18, 2013·Updated Jul 23, 2019

In Brief

A Phase 1 clinical trial evaluating Eribulin-LF for Solid Tumors. Completed, enrolled 62 participants across 4 sites.

Detailed Summary

Study E7389-E044-112 is a Phase 1 study designed to assess the safety, tolerability and preliminary efficacy of eribulin-liposomal formulation (E7389-LF) in patients with solid tumors. This dose-escalation study will determine the maximum tolerated dose, dosing schedules tested, the dose schedule regimen with a more favorable tolerability profile, and a preliminary indication of efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2013
Enrollment StartDec 11, 2012
Primary CompletionOct 1, 2015
Study CompletionMay 17, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.8 years ago

Interventions

Eribulin-LFdrug